Can famotidine cause gynaecomastia? This is a question that occasionally arises among patients taking this widely used H2 receptor antagonist for conditions such as gastro-oesophageal reflux disease (GORD) or peptic ulcer disease. Based on current clinical evidence, famotidine is not established as a cause of gynaecomastia — unlike cimetidine, which carries a well-documented risk. However, isolated case reports exist, and breast changes in males always warrant proper medical evaluation. This article examines the evidence, compares risks across H2 blockers, and outlines when to seek medical advice.

Famotidine and Gynaecomastia: What the Evidence Shows

Famotidine is not recognised as a cause of gynaecomastia in the BNF or UK SmPC; unlike cimetidine, it has no established hormonal mechanism linking it to breast tissue growth in males.

Famotidine is a widely used H2 receptor antagonist prescribed for conditions such as gastro-oesophageal reflux disease (GORD), peptic ulcer disease, and excess stomach acid production. One question that occasionally arises among patients and clinicians is whether famotidine can cause gynaecomastia — the benign enlargement of glandular breast tissue in males.

Based on current evidence, there is no established association between famotidine and gynaecomastia. Unlike cimetidine, another H2 blocker with a well-documented association with this side effect, famotidine has not been shown in clinical trials or large observational studies to cause meaningful hormonal disruption leading to breast tissue growth. The British National Formulary (BNF) and the UK Summary of Product Characteristics (SmPC) for famotidine products do not list gynaecomastia as a recognised adverse effect, though it is advisable to check the specific product label via the electronic Medicines Compendium (eMC), as labelling can vary between licensed products.

Experiencing these side effects? Our pharmacists can help you navigate them →

That said, isolated case reports do exist in the medical literature describing gynaecomastia in patients taking famotidine, though causality has not been firmly established in these instances. It is important to distinguish true gynaecomastia — which involves proliferation of glandular, subareolar breast tissue and is often tender — from pseudogynaecomastia, which is caused by adipose tissue accumulation and is not hormonally driven. This distinction has clinical significance and affects the investigation and management approach.

Gynaecomastia has multiple potential causes, including obesity, liver disease, hypogonadism, thyroid dysfunction, and other medications, making it difficult to attribute the condition to any single drug without careful clinical assessment. Patients who notice breast swelling or tenderness whilst taking famotidine should seek a medical review to explore all possible underlying causes. A thorough medication history, physical examination, and hormonal evaluation are typically the first steps in investigation.

How H2 Blockers May Affect Hormone Levels

Cimetidine causes gynaecomastia by blocking androgen receptors and inhibiting oestrogen metabolism; famotidine lacks this anti-androgenic activity due to its different chemical structure.

To understand why some H2 receptor antagonists are associated with gynaecomastia, it helps to consider their pharmacological mechanisms. H2 blockers work by competitively inhibiting histamine at the H2 receptors on gastric parietal cells, thereby reducing stomach acid secretion. However, some drugs in this class — particularly cimetidine — also interact with androgen receptors, which can disrupt the balance between oestrogen and testosterone.

Cimetidine is the most notable example. It acts as an anti-androgen by:

• Blocking dihydrotestosterone (DHT) binding to androgen receptors

• Inhibiting cytochrome P450 enzymes involved in oestrogen metabolism

• Potentially increasing circulating oestrogen levels relative to testosterone

This hormonal imbalance can stimulate breast glandular tissue in males, resulting in gynaecomastia. These mechanisms are well described in the BNF and cimetidine's SmPC. Famotidine, by contrast, has a much higher selectivity for H2 receptors and does not demonstrate clinically established anti-androgenic activity in pharmacological studies. Its chemical structure differs significantly from cimetidine, and it lacks the imidazole ring thought to be responsible for cimetidine's anti-androgenic properties.

Nevertheless, the endocrine system is complex, and individual variation in drug metabolism — influenced by factors such as genetics, liver function, and concurrent medications — means that unexpected hormonal effects cannot be entirely excluded in all patients. If a patient develops gynaecomastia whilst on famotidine and no other cause is identified after thorough investigation, a trial withdrawal of the medication under medical supervision may be considered, though this should always be guided by a GP or specialist.

Comparing the Risk Across H2 Receptor Antagonists

Cimetidine carries the highest gynaecomastia risk among H2 blockers; famotidine has the lowest risk profile, and PPIs — the current UK first-line treatment — have no established association with gynaecomastia.

When evaluating the risk of gynaecomastia across the H2 blocker class, a clear hierarchy emerges based on available clinical evidence:

• Cimetidine carries the highest risk and is well-documented as a cause of gynaecomastia, particularly at higher doses and with prolonged use. It is now rarely prescribed in the UK for this and other reasons, including its extensive drug interactions via cytochrome P450 inhibition.

• Ranitidine was previously available in the UK but was suspended and subsequently withdrawn from the market in 2020 following MHRA and EMA communications regarding N-nitrosodimethylamine (NDMA) contamination — a concern unrelated to gynaecomastia. Some case reports of gynaecomastia existed with ranitidine, though the risk was considered lower than with cimetidine.

• Famotidine and nizatidine are generally considered to have a much lower risk profile for hormonal side effects, with famotidine in particular showing minimal anti-androgenic activity in pharmacological studies.

For patients who require long-term acid suppression and have concerns about hormonal side effects, famotidine is often considered a preferable option over cimetidine. However, proton pump inhibitors (PPIs) such as omeprazole or lansoprazole — which work via a different mechanism entirely — are now the first-line treatment for most acid-related conditions in the UK, as recommended by NICE NG1: Gastro-oesophageal reflux disease and dyspepsia in adults. PPIs do not have an established association with gynaecomastia, though rare case reports exist in the literature; clinicians should assess any temporal relationship between PPI initiation and new breast symptoms. PPIs have their own side effect profile that should be discussed with a clinician.

When to Speak to a GP or Pharmacist

Males should see a GP promptly for any breast swelling, tenderness, or lump; hard, irregular, or rapidly enlarging lumps require urgent same-day assessment and possible 2-week-wait cancer referral per NICE NG12.

Whilst gynaecomastia caused by medication is generally benign and reversible upon stopping the offending drug, it is important not to dismiss breast changes in males without proper evaluation. There are several situations in which prompt medical advice should be sought.

Contact your GP if you notice:

• Swelling, tenderness, or a lump beneath one or both nipples

• Breast changes that persist for more than two to three weeks

• Nipple discharge of any kind

• Breast changes accompanied by other symptoms such as fatigue, weight changes, or testicular abnormalities

Seek urgent medical attention (same-day or urgent GP appointment) if you notice any of the following red-flag features, which may warrant an urgent 2-week-wait cancer referral in line with NICE NG12: Suspected cancer: recognition and referral:

• A hard, irregular, or fixed breast lump

• Skin tethering, dimpling, or puckering

• Nipple retraction, ulceration, or bloody discharge

• A rapidly enlarging unilateral mass

• Swollen lymph nodes in the armpit

• Unilateral nipple changes in a man aged 50 or over

A GP will typically take a full medication history and perform a physical examination, including assessment of the testes. Blood tests may include testosterone, oestradiol, LH, FSH, prolactin, liver function tests (LFTs), thyroid function tests (TFTs), and serum hCG if a testicular or other germ cell tumour is suspected. Testicular ultrasound may be arranged where clinically indicated. In some cases, referral to an endocrinologist or breast surgeon may be appropriate — particularly if the cause remains unclear or if the gynaecomastia is causing significant physical or psychological distress. Further guidance is available via NICE CKS: Gynaecomastia.

Do not stop taking famotidine or any prescribed medication without first speaking to your GP or pharmacist. Abrupt discontinuation of acid-suppressing therapy can lead to rebound acid hypersecretion and worsening symptoms. A pharmacist can also provide useful guidance on whether any other medications you are taking — including over-the-counter products or supplements — may be contributing to breast changes. Many drugs, including spironolactone, some antipsychotics, and anabolic steroids, are well-recognised causes of gynaecomastia.

Alternative Treatments for Acid Reflux in the UK

PPIs such as omeprazole and lansoprazole are the NICE-recommended first-line treatments for GORD in the UK and have no established association with gynaecomastia.

For patients who are concerned about the potential side effects of famotidine, or for whom it is not providing adequate symptom control, there are several alternative treatments available in the UK. The choice of therapy should always be guided by a GP or pharmacist based on the individual's symptoms, medical history, and relevant NICE guidance (NICE NG1).

Have questions about your medication? Our pharmacists are here to help →

Proton pump inhibitors (PPIs) are the most commonly prescribed first-line treatment for GORD and peptic ulcer disease in the UK. Options include:

• Omeprazole — available over the counter at lower doses and on prescription at higher doses

• Lansoprazole — widely used and available in dispersible formulations; prescription-only

• Esomeprazole and pantoprazole — prescription-only alternatives for patients who do not respond to other PPIs

PPIs work by irreversibly inhibiting the hydrogen-potassium ATPase enzyme (the 'proton pump') in gastric parietal cells, producing more profound and sustained acid suppression than H2 blockers. They do not interact with androgen receptors and have no established association with gynaecomastia. NICE NG1 recommends using the lowest effective dose for the shortest necessary duration, with regular review of ongoing need.

For mild or infrequent symptoms, antacids (such as Gaviscon or calcium carbonate preparations) and alginates can provide short-term symptomatic relief without systemic hormonal effects. Lifestyle modifications — including weight management, dietary changes, elevating the head of the bed, and reducing alcohol and caffeine intake — are also recommended by NICE as important adjuncts to pharmacological treatment.

In cases of refractory GORD or where long-term PPI use is a concern, referral for specialist assessment and possible endoscopy may be appropriate. Surgical options such as laparoscopic fundoplication exist for carefully selected patients.

MHRA Guidance and Reporting Side Effects

The MHRA has not issued safety warnings linking famotidine to gynaecomastia; suspected side effects can be reported via the Yellow Card scheme at yellowcard.mhra.gov.uk.

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK body responsible for monitoring the safety of medicines and medical devices. The MHRA continuously reviews post-marketing surveillance data, including spontaneous adverse event reports, to identify any emerging safety signals associated with licensed medicines such as famotidine.

At present, the MHRA has not issued any specific safety warnings linking famotidine to gynaecomastia. The current UK SmPC for famotidine products does not include gynaecomastia in its list of adverse reactions, which is consistent with the broader clinical evidence base. Patients and clinicians can verify the most up-to-date product information via the electronic Medicines Compendium (eMC) at medicines.org.uk.

The MHRA operates the Yellow Card scheme, which allows patients, carers, and healthcare professionals to report suspected adverse drug reactions — including unexpected or unlisted side effects. Reporting through the Yellow Card scheme is an important part of pharmacovigilance and helps the MHRA detect rare or previously unrecognised side effects that may not have emerged during clinical trials.

If you suspect that famotidine or any other medicine has caused an unexpected side effect, you can report it via:

• The Yellow Card website: yellowcard.mhra.gov.uk

• The Yellow Card app, available on iOS and Android

• By speaking to your GP, pharmacist, or nurse, who can submit a report on your behalf

Healthcare professionals are also encouraged to report suspected adverse reactions, particularly where the reaction is serious or unexpected. Collective reporting helps build a more complete picture of a medicine's safety profile and ultimately protects patients across the UK.

Frequently Asked Questions